Resonance Specialties Limited

Basic Materials — Chemicals · BSE

₹198.95+₹8.10 (+4.24%)

DalalBaazaar Score

72 / 100

🟢 Good

Verdict

REASONABLE

Risk

High

Driven by high debt relative to equity, micro-cap size, which brings thin liquidity.

In simple words: Strong business and financial position, with both sales and profits growing well. Debt is the main factor to watch.

Decision support, not a buy or sell call.

As of 18 Oct 2026, 6:07 pm

Mixed / neutral. No major red flags jump out, but nothing here screams "obviously cheap" either. This is a name that needs a peer comparison and a view on near-term earnings triggers before sizing a position.

Understanding the Business

Company site ↗

The 60-second version of Resonance Specialties Limited — what it does, how it earns, and who it competes with, before any of the numbers below.

What does this company do?

Resonance Specialties Limited engages in the manufacture and marketing of specialty chemicals in India and internationally.

IndustryChemicals

SectorBasic Materials

Employees74

Annual revenue₹89 Cr

How does it make money?

Turns over ₹89 Cr a year. Of every ₹100 of sales, about ₹12 reaches shareholders as profit, with ₹17 left at the operating level before interest, tax and depreciation. Each of its 74 employees supports ₹1.21 Cr of revenue a year, the signature of a capital- or asset-led business.

EBITDA margin17.3%

Net margin11.7%

Revenue / employee₹1.21 Cr

Who are its competitors?

The closest listed comparisons in its industry are PIDILITE INDUSTRIES LTD, SRF LTD, UPL LIMITED. These are the companies its valuation and returns are measured against elsewhere in this report.

PIDILITE INDUSTRIES LTDP/E 57.8x · ROE 24.4%

SRF LTDP/E 33.8x · ROE 15.4%

UPL LIMITEDP/E 21.5x · ROE 6.1%

What is its competitive advantage?Some evidence

ROCE of 18.8% is above what capital typically costs, which suggests some pricing power, though not yet the sustained, wide gap that marks a durable advantage.

ROCE18.8%

ROE14.2%

Peer median ROE15.4%

What has been driving growth?

Sales and margins have both contributed to where profit is now. Over 3 years revenue moved +53% while net margin moved +36% relative to itself. What this cannot tell you is which products, customers or geographies did the work — that lives in the segment disclosures of the annual report.

Revenue effect+53%

Margin effect+36%

DalalBaazaar Score

72/ 100

Good

Weighted across six categories. Every point is explained below.

✓ Beta of 0.58 — historically steadier than the index
✗ Micro Cap: thinner liquidity and sharper drawdowns are normal
✗ High leverage magnifies any downturn in earnings
✗ Profits have swung sharply from year to year — earnings are hard to forecast
✗ Trading within 10% of its 52-week high — entries here carry more pullback risk

Quality vs. Valuation

Company Quality

77/ 100

Good

How good the business is, ignoring the share price entirely.

Valuation

77/ 100

Cheap

What you are being asked to pay, ignoring how good the business is.

A good business currently available at an undemanding price — the combination this framework is built to look for.

Historical Valuation

Current P/E

15.8x

3Y Median

23.4x

40 monthly readings · mean 26.2x · range 13.7x–47.9x

Sector Median

33.8x

median of 3 sector peers

🟢Current valuation is approximately 32% below its 3y median of 23.4x. Cheaper than its own history, which is worth a reason too: the market may be pricing in something the backward-looking numbers do not show.

🟢Against its sector it trades 53% below the peer median of 33.8x.

vs. its own history

Cheap

23.4x median over 40 months · -32%

vs. sector peers

Cheap

33.8x median of 3 peers · -53%

vs. generic bands

Fair

15x–35x

P/E (Trailing)

15.8x

P/B

3.14x

EV/EBITDA

15.0x

PEG

0.57

Dividend Yield

0.50%

What's Good / What's Bad

🟢 What's Going Well6

Margins are improving
EBITDA margin is up from 14.3% to 17.3% over 3 years.
Cash flow has turned positive
Free cash flow moved from negative to positive over 3 years.
Return on equity is rising
ROE has improved from 9.0% to 14.2%.
Return on capital is rising
ROCE has improved from 11.6% to 18.8%.
Valuation below its historical average
At 15.8x the stock trades 32% below its own median of 23.4x.
Consistently profitable
Profitable in every one of the last 4 reported years.

🔴 What Needs Attention0

Nothing stands out as clearly deteriorating on the years of data available.

Red Flags

1 item require attention · 1 high

🔴High leverageFinancial
Debt/Equity of 3.06x — earnings must service borrowings before shareholders see anything.

Investment Thesis

🟢 Bull CaseWhat could make this work?

Capital compounds at a high rate
ROCE of 18.8% means each rupee reinvested earns well above what capital costs. If the company can keep deploying at this rate, growth creates value rather than just consuming cash.
Margin expansion has further to run
EBITDA margin has risen from 14.3% to 17.3%. If that holds, profit compounds faster than sales and today's multiple looks cheaper in hindsight than it does now.
Priced below its own history
The stock trades 32% below its own median multiple. If the business performs as it has and simply re-rates back to normal, that gap is return on its own.
Cheaper than its peers
It trades 53% below the sector median. Either the market sees a problem the numbers do not show, or the discount closes.
Earnings have proved durable
Profitable in every one of the last 4 reported years. Consistency lowers the risk that any single bad year is structural rather than cyclical.

🔴 Bear CaseWhat could go wrong?

Leverage amplifies any setback
Debt/Equity of 3.06x. Interest is payable whether or not the business has a good year.
Earnings are hard to forecast
Profit has swung sharply from year to year, so any single year — good or bad — is a weak guide to the next. Cyclical earnings deserve lower multiples for that reason.
Size brings its own risk
Micro Cap businesses are thinly traded, so exits are harder in a falling market and single events move the price more than they would for a larger company.

🟡 Key Things to WatchMeasurable tripwires, set against where this company stands today

1Revenue growth stays above 11% a year✓ 15.2% CAGR
Latest reported year was 53.2%. The bar is set below the established compounding rate, so ordinary variation does not trip it.
2EBITDA margin holds above 15%✓ 17.3%
Two points below today's level — enough room for noise, tight enough to catch real compression.
3Free cash flow remains positive✓ ₹14 Cr
Profit that never becomes cash eventually stops being profit.
4Debt / EBITDA stays below 2x✓ 0.1x
The ratio lenders write covenants against; it survives a small or negative equity base, unlike Debt/Equity.
5ROCE stays above 16%✓ 18.8%
Falling returns on capital are usually competition arriving, and show up here before they reach the margin.

Investment Checklist

8 / 11 checks passed

✗ Strong return on equity (ROE ≥ 15%)
✓ Strong return on capital employed (ROCE ≥ 15%)
✓ Healthy net margin (≥ 10%)
✓ Generates positive free cash flow
✗ Manageable leverage (Debt/Equity < 1.0)
✓ Adequate short-term liquidity (Current Ratio ≥ 1.0)
✓ Revenue growing year-over-year
✓ Profit growing year-over-year
✓ Not trading at an extreme valuation (P/E < 40x)
✗ Not buying right at the 52-week high
✓ Short-term technical trend isn't bearish

Price history

Quick Metrics

5 good · 5 neutral · 1 weak

Market Cap

₹230 Cr

Micro Cap

Smaller company — thin liquidity and deep drawdowns are normal here

P/E (Trailing)

15.8x

Fair

Fairly valued against the generic band

P/B Ratio

3.14x

Fair

Moderate premium to the company's book value

EPS (TTM)

₹12.58

Profitable

Profitable on a per-share basis

ROE

14.2%

Moderate

Moderate capital efficiency

ROCE

18.8%

Strong

Earns comfortably above its likely cost of capital

Debt/Equity

3.06x

High

High leverage

Revenue Growth (YoY)

53.2%

Healthy

Healthy top-line growth

Profit Growth (YoY)

253.2%

Healthy

Profits growing at a healthy clip

Dividend Yield

0.50%

Modest

Small cash return — most of the return has to come from the price

Free Cash Flow

₹14 Cr

Cash generative

Generates cash even after funding its capex

More Metrics

CMP

₹198.95

Operating Margin

21.9%

Good

Healthy core-business profitability

Net Margin

14.3%

Good

Strong bottom-line conversion

Current Ratio

4.12

Comfortable

Healthy short-term liquidity

Beta (vs Nifty)

0.58

Defensive

Steadier than the market

52W Range Position

92%

Near high

Near its 52-week high

Technical Snapshot

SMA 20 / SMA 50

184.7 / 174.6

Bullish alignment (short > long)

Price vs SMA 200

Above

Long-term uptrend

RSI (14)

53.9

Neutral momentum

Financial Trend (4-Year)

Metric	FY23	FY24	FY25	FY26	3Y CAGR
Revenue	₹58 Cr	₹55 Cr	₹77 Cr	₹89 Cr	+15.2%
EBITDA	₹8 Cr	₹6 Cr	₹11 Cr	₹15 Cr	+22.8%
EBITDA Margin	14.3%	10.5%	14.9%	17.3%	—
PAT (Net Profit)	₹5 Cr	₹3 Cr	₹7 Cr	₹10 Cr	+27.6%
EPS	₹4.33	₹2.56	₹5.69	₹9.01	+27.6%
ROE	9.0%	5.2%	10.3%	14.2%	—
ROCE	11.6%	6.9%	13.6%	18.8%	—
Total Debt	₹2 Cr	₹4 Cr	₹3 Cr	₹2 Cr	-0.7%
Free Cash Flow	-₹16 Cr	-₹0 Cr	-₹4 Cr	₹14 Cr	—

🟢 Revenue has grown at 15.2% a year over 3 years.

🟢 EBITDA has grown at 22.8% a year over 3 years.

🟢 EBITDA Margin has risen from 14.3% to 17.3% over 3 years (+3.0 pts).

🟢 PAT (Net Profit) has grown at 27.6% a year over 3 years.

🟢 EPS has grown at 27.6% a year over 3 years.

🟢 ROE has risen from 9.0% to 14.2% over 3 years (+5.2 pts).

🟢 ROCE has risen from 11.6% to 18.8% over 3 years (+7.1 pts).

🟡 Total Debt has been broadly flat over 3 years (-0.7% a year).

🟢 Free Cash Flow has turned positive, from -₹16 Cr to ₹14 Cr.

Balance Sheet & Cash Flow — FY2026

Total Assets

₹92 Cr

Total Liabilities

₹19 Cr

Total Debt

₹2 Cr

Cash & Equivalents

₹0 Cr

Operating Cash Flow

₹17 Cr

Capex

-₹4 Cr

Shareholding (proxy)

Institutional Holding

0.0%

Insider Holding

62.8%

Corporate Actions

Dividend Rate

₹1

Ex-Dividend Date

28 Jul 2026

Peer Comparison

Company	P/E	ROE
PIDILITE INDUSTRIES LTD	57.8x	24.4%
SRF LTD	33.8x	15.4%
UPL LIMITED	21.5x	6.1%

Recent News

2 positive4 general

Resonance Specialties shareholders approve dividend, face dissent on related party deal

scanx.trade, 04 AugCapital return

🟢Potentially positiveCash or shares returned to holders. A buyback is only good value if the shares were cheap when bought.

Resonance Specialties Ltd. Shareholding Pattern – Promoters, FIIs & DIIs

Value Research, 29 Aug

Resonance Specialties touches the roof on getting nod to purchase manufacturing facility in Madhya Pradesh

Investment Guru India, 04 Aug

Resonance Specialties net profit surges 252% in Q1FY27 on export strength

scanx.trade, 04 AugResults

🟢Potentially positiveReported improvement. Check whether it came from volume, price or a one-off item before treating it as a trend.

Jaysynth Orgochem (BSE:524592) - Stock Analysis

Simply Wall Street, 11 Oct

Resonance Specialties Ltd. Share Price Near 52-Week High

Univest, 12 Aug

Watch Items

Trading very close to its 52-week high — momentum-driven entries here carry more mean-reversion risk.
Cross-check against the company's latest quarterly filing / investor presentation before acting.

DalalBaazaar Thesis

🟢Business QualityStrong14.5/20

🟢Financial HealthStrong13.9/20

🟢GrowthStrong18.5/20

🟢ProfitabilityStrong10.7/15

🟢ValuationAttractive10.7/15

🔴RiskHigh4/10

Attractive on both counts

A good business currently available at an undemanding price — the combination this framework exists to look for. The work left is qualitative: whether the advantage the numbers imply is one you can identify and expect to last. 1 high-severity red flag sits above this conclusion and should be read first.

This thesis breaks if

✓Revenue growth stays above 11% a year15.2% CAGR
✓EBITDA margin holds above 15%17.3%
✓Free cash flow remains positive₹14 Cr
✓Debt / EBITDA stays below 2x0.1x
✓ROCE stays above 16%18.8%